Lisata Therapeutics appoints Jeff Farrow to Boa...
Alpha Vantage · Pluang · · AI-summarised by FinFlash
Lisata Therapeutics has appointed Jeffrey Farrow, a seasoned biopharma CFO, to its Board of Directors, expanding it to eight members. Farrow will join the Audit Committee, bringing over 15 years of public company experience to support Lisata's financial leadership and ongoing Phase 2b clinical programs. This strategic addition aims to strengthen the company as it advances its drug development pipeline.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.